Pharmacoepidemiology in Japan: medical databases and research achievements.
Pharmacoepidemiology in Japan: medical databases and research achievements.
复制标题
DOI：
10.1186/s40780-015-0016-5
复制
发表时间：
2015
影响因子：
1
通讯作者：
Kawakami K
中科院分区：
文献类型：
--
作者：
Tanaka S;Seto K;Kawakami K
药物流行病学涉及开发新模型以预测药物开发阶段的安全性，制定与临床试验相关的各种指南和政策，药物警戒，建立和实施上市后研究的风险管理，以及医疗和社会福利部门的成本效益研究。对药品的安全性、有效性和成本的评估必须以不同的方式进行。最近，医学中的“大数据”已经成为流行病学研究的驱动力，这些研究试图解决临床环境中的问题。此外，考虑到政府的财政状况，追求成本效益也很重要。利用与费用数据相联系的流行病学数据进行流行病学和经济研究，将为适当分配卫生资源提供科学依据。
Pharmacoepidemiology involves development of new models to predict safety in the development stages of pharmaceutical products, development of various guidelines and policy related to clinical trials, pharmacovigilance, establishment and implementation of risk management in postmarketing studies, and cost-effectiveness research in medical and social welfare sectors. Evaluations of safety, efficacy, and costs of pharmaceutical products must be developed in a different way. More recently, “big data” in medicine have become the driving force behind epidemiological studies that attempt to solve questions in the clinical setting. Furthermore, it is important to pursue cost-effectiveness considering the government’s financial condition. Epidemiologic and economic research utilizing epidemiological data linked to cost data will provide scientific evidence for appropriate distribution of health resources.